Last reviewed · How we verify

Oritavancin Injection

University of Pennsylvania · FDA-approved active Small molecule Under review

Oritavancin Injection is a Lipoglycopeptide antibiotic Small molecule drug developed by University of Pennsylvania. It is currently FDA-approved for Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms including MRSA.

Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to peptidoglycan precursors and disrupting cross-linking.

Oritavancin Injection is a small molecule used to treat Staphylococcus Aureus Bacteremia and Staphylococcus Aureus Endocarditis. It is administered via injection.

At a glance

Generic nameOritavancin Injection
SponsorUniversity of Pennsylvania
Drug classLipoglycopeptide antibiotic
TargetBacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Oritavancin binds to D-Ala-D-Ala peptidoglycan precursors and also interacts with the bacterial cell membrane, preventing proper cell wall formation. This dual mechanism of action makes it effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. The drug is bactericidal and has a long half-life allowing for single-dose administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oritavancin Injection

What is Oritavancin Injection?

Oritavancin Injection is a Lipoglycopeptide antibiotic drug developed by University of Pennsylvania, indicated for Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms including MRSA.

How does Oritavancin Injection work?

Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to peptidoglycan precursors and disrupting cross-linking.

What is Oritavancin Injection used for?

Oritavancin Injection is indicated for Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms including MRSA.

Who makes Oritavancin Injection?

Oritavancin Injection is developed and marketed by University of Pennsylvania (see full University of Pennsylvania pipeline at /company/university-of-pennsylvania).

What drug class is Oritavancin Injection in?

Oritavancin Injection belongs to the Lipoglycopeptide antibiotic class. See all Lipoglycopeptide antibiotic drugs at /class/lipoglycopeptide-antibiotic.

What development phase is Oritavancin Injection in?

Oritavancin Injection is FDA-approved (marketed).

What are the side effects of Oritavancin Injection?

Common side effects of Oritavancin Injection include Headache, Nausea, Infusion site reactions, Diarrhea, Vomiting.

What does Oritavancin Injection target?

Oritavancin Injection targets Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II and is a Lipoglycopeptide antibiotic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing